Passing the Torch: Advancing Bispecific Therapy Beyond the Academic Setting for Multiple Myeloma

Image Credit: Zach Fox Photography

Meeting Objectives:

• • Describe key challenges and evolving strategies in ensuring continuity of care for patients with relapsed/refractory multiple myeloma (R/R MM) receiving bispecific antibody therapies during transitions between academic and community settings.
  • Evaluate real-world patient cases to assess how clinical trial data and updated guidelines can be translated across care settings to optimize the delivery of bispecific antibody therapy for R/R MM.
  • Examine the collaborative role of pharmacists in managing bispecific antibody therapies across transitions of care, including education, toxicity management, therapy sequencing, and logistical coordination between institutions.